Bone morphogenetic protein receptor type 1A (BMPR1A) (BMPR1A)

Bone morphogenetic protein receptor type 1A (BMPR1A), also known as ALK3, is a transmembrane serine/threonine kinase that serves as a primary type I receptor for the bone morphogenetic protein (BMP) signaling pathway (UniProt, PubMed) [1.3.1, 1.3.3]. Upon binding to ligands such as BMP-2 or BMP-4, BMPR1A forms a heterotetrameric complex with type II receptors, initiating a signaling cascade that phosphorylates SMAD1/5/8 proteins to regulate gene expression (Patsnap, NIH) [1.2.1, 1.4.3]. This pathway is essential for embryonic development, particularly mesoderm specification, and is a critical regulator of bone and cartilage homeostasis (Wikipedia, NIH) [1.3.2, 1.4.4]. Mutations in the BMPR1A gene are a major cause of Juvenile Polyposis Syndrome (JPS), a condition characterized by gastrointestinal hamartomatous polyps and an increased risk of colorectal cancer (UniProt, NIH) [1.3.3, 1.4.1]. Beyond hereditary syndromes, BMPR1A is implicated in various sporadic cancers, including breast and lung cancer, where it can promote tumor progression and metastasis (NIH) [1.4.2]. Therapeutic strategies include the use of recombinant BMP ligands for bone repair and small-molecule inhibitors or antibodies to block aberrant signaling in cancer (Patsnap, NIH) [1.2.3, 1.4.2]. However, the high structural similarity between BMPR1A and other ALK family receptors presents challenges for achieving selectivity, potentially leading to off-target effects and safety concerns such as vascular complications or heterotopic ossification (Patsnap, NIH) [1.2.3, 1.3.4].

Other names

ALK3CD292ACVRLK3SKR5BMR1AActivin receptor-like kinase 3

Kinase inhibition, receptor activation, and competitive ligand binding to modulate the BMP-SMAD signaling pathway.